Sarepta Therapeutics (SRPT) Payables (2010 - 2026)

Sarepta Therapeutics' Payables history runs 17 years deep, the most recent figure standing at $70.4 million for Q1 2026.

• In Q1 2026, Payables fell 54.92% year-over-year to $70.4 million; the TTM figure through Mar 2026 stood at $70.4 million (down 54.92% YoY), while the FY2025 annual figure was $280.8 million, up 30.96% from the prior year.
• Payables for Q1 2026 stood at $70.4 million, down from $280.8 million in the prior quarter.
• The five-year high for Payables was $280.8 million in Q4 2025, with the low at $54.0 million in Q1 2022.
• The 5-year median for Payables is $107.4 million (2024), against an average of $121.4 million.
• The sharpest annual moves came in 2022 and 2026: Payables jumped 168.24% in 2022, then plunged 54.92% in 2026.
• Sarepta Therapeutics' Payables stood at $95.9 million in 2022, then surged by 72.01% to $164.9 million in 2023, then soared by 30.03% to $214.4 million in 2024, then surged by 30.96% to $280.8 million in 2025, then plunged by 74.94% to $70.4 million in 2026.
• Business Quant data shows SRPT's Payables at $70.4 million in Q1 2026, $280.8 million in Q4 2025, and $94.0 million in Q3 2025.